AU2003259965A1 - Methods and compositions for modulating amyloid beta - Google Patents

Methods and compositions for modulating amyloid beta

Info

Publication number
AU2003259965A1
AU2003259965A1 AU2003259965A AU2003259965A AU2003259965A1 AU 2003259965 A1 AU2003259965 A1 AU 2003259965A1 AU 2003259965 A AU2003259965 A AU 2003259965A AU 2003259965 A AU2003259965 A AU 2003259965A AU 2003259965 A1 AU2003259965 A1 AU 2003259965A1
Authority
AU
Australia
Prior art keywords
compositions
methods
amyloid beta
modulating amyloid
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259965A
Other versions
AU2003259965A8 (en
Inventor
Maria Kounnas
Aaron Patrick
Gonul Velicelebi
Steven Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TorreyPines Therapeutics Inc
Original Assignee
TorreyPines Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TorreyPines Therapeutics Inc filed Critical TorreyPines Therapeutics Inc
Publication of AU2003259965A1 publication Critical patent/AU2003259965A1/en
Publication of AU2003259965A8 publication Critical patent/AU2003259965A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003259965A 2002-08-20 2003-08-20 Methods and compositions for modulating amyloid beta Abandoned AU2003259965A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40541702P 2002-08-20 2002-08-20
US60/405,417 2002-08-20
US41197402P 2002-09-18 2002-09-18
US60/411,974 2002-09-18
PCT/US2003/026173 WO2004018997A2 (en) 2002-08-20 2003-08-20 Methods and compositions for modulating amyloid beta

Publications (2)

Publication Number Publication Date
AU2003259965A1 true AU2003259965A1 (en) 2004-03-11
AU2003259965A8 AU2003259965A8 (en) 2004-03-11

Family

ID=31949893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259965A Abandoned AU2003259965A1 (en) 2002-08-20 2003-08-20 Methods and compositions for modulating amyloid beta

Country Status (2)

Country Link
AU (1) AU2003259965A1 (en)
WO (1) WO2004018997A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003287524A1 (en) * 2002-11-04 2004-06-07 Icogenex Corporation Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
EP1563066A4 (en) * 2002-11-04 2006-06-07 Bioarctic Neuroscience Ab Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
JP4847868B2 (en) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド Compounds and their use in the regulation of amyloid beta
US7892845B2 (en) 2005-04-06 2011-02-22 Washington University In St. Louis Methods for measuring the metabolism of neurally dervied biomolecules in vivo
PL1954718T3 (en) 2005-11-30 2015-04-30 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
JP5486808B2 (en) 2005-11-30 2014-05-07 アッヴィ・インコーポレイテッド Monoclonal antibody against amyloid beta protein and use thereof
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7618944B2 (en) 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
NZ585528A (en) 2007-11-21 2012-08-31 Pharmaxis Ltd Haloallylamine inhibitors of ssao/vap-1 and uses therefor
CA2725326A1 (en) * 2008-05-23 2009-11-26 University Of Rochester Compositions and methods relating to detection of soluble e-cadherin in neurodegenerative disease
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
CN104744591B (en) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 Amyloid beta binding proteins
WO2011163636A2 (en) 2010-06-24 2011-12-29 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
CN105348387B (en) 2010-08-14 2020-08-25 Abbvie 公司 Amyloid beta binding proteins
ES2668300T3 (en) 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh 3-haloamidine substituted SSAO inhibitors and uses thereof
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
EP3760235A1 (en) 2014-09-30 2021-01-06 Washington University Tau kinetic measurements
MX2017005715A (en) 2014-10-31 2018-02-23 Massachusetts Gen Hospital Potent gamma-secretase modulators.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies

Also Published As

Publication number Publication date
WO2004018997A3 (en) 2005-06-23
WO2004018997A2 (en) 2004-03-04
AU2003259965A8 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2003259965A1 (en) Methods and compositions for modulating amyloid beta
AU2003295511A1 (en) Methods and compositions for diagnosing dysplasia
EP1578940A3 (en) Methods and compositions for diagnosing dysplasia
AU2003241478A1 (en) Nanoparticulate sterol formulations and sterol combinations
AU2003274652A1 (en) Compounds, compositions and methods for modulating fat metabolism
AU2003297195A1 (en) Total disc implant
AU2003266058A1 (en) Antimicrobial composition and method for use
AU2003226094A1 (en) Compounds and methods
AU2003285288A1 (en) Composition
AU2003234794A1 (en) Composition and method for temporarily fixing solid
AU2003267644A1 (en) Dental compositions and methods
AU2003256805A1 (en) Compounds compositions and methods
AU2003287443A1 (en) Compositions and methods for pain reduction
AU2003252324A1 (en) Fat composition
AU2003211453A1 (en) External compositions for the skin
AU2003236353A1 (en) Photopolymerizable composition
AU2003235708A1 (en) Polytartrate composition
AU2003266815A1 (en) Immunoglobulin compositions and methods
AU2003225104A1 (en) Composition for reducing malodors and method for using the same
AU2003276129A1 (en) Compositions and methods for darkening the skin
AU2002950831A0 (en) Rheometer
AU2003208411A1 (en) Anti-glycolytic composition
AU2003269904A1 (en) Antigen-polymer compositions
AU2003213663A1 (en) Methods and compositions for regulating adipogenesis
EP1576109A3 (en) Methods and compositions for categorizing patients

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase